7 March 2019

Deviating from the treatment guideline for the orphan drug eculizumab for patients with aHUS has saved 17 million euros in healthcare costs. This has been shown by the doctoral study of Kioa Wijnsma, theme Renal disorders, which she will defend on 8 March. The results of her study pave the way for more research into reducing the costs of administering expensive drugs to treat rare diseases.

The lives of patients with atypical hemolytic uremic syndrome (aHUS), a severe kidney disease, changed drastically with the availability of the orphan drug eculizumab in 2011. Eculizumab is a very effective drug, but also one of the most expensive in the world. According to the manufacturere, the drug must be administered every two weeks for life, which costs up to €500,000 per patient per year. However, there is hardly any scientific substantiation of this recommended dosage and use of the product. 

Dose reduction

Kioa Wijnsma discovered that the levels of the drug in the blood of patients that were treated with exulizumab according to the manufacturer’s instructions were seven times higher than necessary. A small-scale study of 20 patients showed that the dose could be drastically reduced. In 17 of the patients, the treatment could be stopped entirely. The other three patients received a reduced dose. In five patients, the aHUS returned after some time, after which the treatment was resumed and could later be stopped again. This did not result in chronic kidney damage. 

Cost reduction

Since the amendment of the Dutch guideline in 2016 according to Wijnsma's insights, over €17 million in healthcare costs have been saved. According to data from the Dutch Healthcare Authority, the expenditure on such expensive drugs amounted to more than €2 billion in 2017. In terms of total costs per patient for such drugs, eculizumab is in sixth place. According to Wijnsma, her study can serve as an example for research into more efficient use of other orphan drugs, independent from the pharmaceutical industry: “Collaboration between patient organizations and medical specialists makes it possible to develop a unique, modified treatment scheme and to evaluate it together on the basis of a national study.” 

CUREiHUS study

For patients with aHUS, eculizumab treatment is now reimbursed by their health insurance as part of an ‘orphan drug arrangement’. A prerequisite for this arrangement is that the patients participate in the CUREiHUS study. The aim of this study is to select the most optimal dose for all patients. The researchers also look for markers in the blood that can predict whether an aHUS patient will relapse if treatment is stopped. A definitive cost-effectiveness analysis will take place after completion of the CUREiHUS study in 2020. 

About aHUS

In aHUS, the complement system, part of the immune system, is disrupted. This complement system is activated in response to infections, but in people with aHUS this system remains permanently active. This causes damage in the body, including the small blood vessels in the kidney. This can eventually lead to chronic kidney failure. However the disease is extremely rare. In the Netherlands, about five children and 15 adults are diagnosed with aHUS annually. Most patients have a genetic predisposition for the disease.
 

Related news items


Bart van de Warrenburg appointed visiting professor at the UKM Medical Centre in Kuala Lumpur

11 November 2019

Neurologist and Principal Investigator at the Donders Institute Bart van de Warrenburg has been appointed visiting professor at the UKM Medical Centre in Kuala Lumpur.

read more

KNAW Van Leersum beurs for Mohammad Alsady

7 November 2019

Mohammad Alsady, theme Disorders of movement, received the “KNAW Van Leersum beurs”.

read more

3D breast ultrasound elastography to improve breast cancer detection

5 November 2019

One out of seven women will be diagnosed with breast cancer during their life. Early detection of breast cancer is important to increase the survival rate. Gijs Hendriks graduated recently on a new technique, 3D elastography, to detect breast cancer better.

read more

Self-management rehabilitation program improves participation in patients with neuromuscular disease

4 November 2019

Yvonne Veenhuizen, Alexander Geurts theme Neurorehabilitation, Baziel van Engelen, theme Disorders of movement, and colleagues, showed that Energetic improves participation in patients with neuromuscular disease. They have published their results in Neurology.

read more

New NFU eBROK® course open for registration

1 November 2019

This platform is not only for researchers who want to obtain their BROK® certificate, but also for researchers who already have a BROK® certificate and want to keep their certification (re-certification).

read more

Emily Klooster wins the NVZF incentive prize

31 October 2019

For the second year in a row, a PhD candidate from the Allied Health Sciences group of IQ Healthcare (RIHS), has won the "Dutch Association for Physiotherapists in the Hospital" incentive prize.

read more